Acticor Biotech SAS Management

Management criteria checks 3/4

Acticor Biotech SAS' CEO is Gilles Avenard, appointed in Oct 2021, has a tenure of 3.08 years. total yearly compensation is €361.67K, comprised of 74% salary and 26% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €47.89K. The average tenure of the management team and the board of directors is 3 years and 2.8 years respectively.

Key information

Gilles Avenard

Chief executive officer

€361.7k

Total compensation

CEO salary percentage	74.0%
CEO tenure	3.1yrs
CEO ownership	1.0%
Management average tenure	3yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gilles Avenard's remuneration changed compared to Acticor Biotech SAS's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€16m
Mar 31 2024	n/a	n/a	-€18m
Dec 31 2023	€362k	€268k	-€19m
Sep 30 2023	n/a	n/a	-€19m
Jun 30 2023	n/a	n/a	-€19m
Mar 31 2023	n/a	n/a	-€17m
Dec 31 2022	€751k	€250k	-€16m
Sep 30 2022	n/a	n/a	-€15m
Jun 30 2022	n/a	n/a	-€14m
Mar 31 2022	n/a	n/a	-€13m
Dec 31 2021	€1m	€173k	-€13m

Compensation vs Market: Gilles's total compensation ($USD376.62K) is about average for companies of similar size in the French market ($USD309.80K).

Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.

CEO

Gilles Avenard (73 yo)

3.1yrs

Tenure

€361,665

Compensation

Dr. Gilles Avenard, M.D serves as Founder at Acticor Biotech SAS and has been its Chief Executive Officer since October 14, 2021 and was its Chairman until June 2021 and serves as its Director. He serves a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gilles Avenard	Founder	3.1yrs	€361.67k	1.02% € 47.9k
Sophie Lebel-Binay	Deputy CEO	no data	€238.94k	no data
Yannick Pletan	Deputy CEO	6.9yrs	€279.91k	no data
Philippe Billiald	Scientific Founder	no data	no data	no data
Martine Jandrot-Perrus	Scientific Founder	no data	no data	no data
Francois Guillet	Chief Financial Officer	less than a year	no data	no data
Laurie Jullien	Head of Regulatory Affairs	no data	no data	no data
Victoria Rutman	Head of Quality Assurance	no data	no data	no data
Elie Toledano	Head of Scientific Affairs & Business Intelligence	3.8yrs	no data	no data
Adeline Meilhoc	Head of Global Clinical Development	2.8yrs	no data	no data
Anouar Sari	Head of Clinical Operations	1.3yrs	no data	no data

3.0yrs

Average Tenure

71yo

Average Age

Experienced Management: ALACT's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gilles Avenard	Founder	no data	€361.67k	1.02% € 47.9k
Alain Munoz	Independent Chairman of the Board	3.4yrs	€80.00k	0.30% € 14.0k
Alain Parthoens	Director	2yrs	no data	no data
Catherine Boule	Director	no data	no data	no data
Rinaldo Del Bono	Director	3.8yrs	no data	3.14% € 147.9k
Patricia Zilliox	Independent Director	1.8yrs	€135.88k	no data
Guillaume Heynen	Observer	2yrs	no data	no data
James Stearns	Observer	2.8yrs	no data	no data
Jean-Pierre Cazenave	Independent Board Member	6yrs	€30.00k	0.0089% € 421.3
Leila Nicolas	Director	no data	no data	no data

2.8yrs

Average Tenure

70.5yo

Average Age

Experienced Board: ALACT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Acticor Biotech SAS Management

Management criteria checks 3/4

Key information

Recent management updates

Acticor Biotech Announces Chief Financial Officer Changes

Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024

Acticor Biotech SAS, Annual General Meeting, Jun 21, 2024

Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Acticor Biotech Announces Chief Financial Officer Changes

Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction

Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024

New major risk - Revenue and earnings growth

Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green Study

Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024

New minor risk - Financial data availability

Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024

Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million.

Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million.

The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack

Acticor Biotech SAS, Annual General Meeting, Jun 21, 2024

New major risk - Share price stability

Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal

Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million.

Forecast to breakeven in 2025

ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke

New minor risk - Share price stability

Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency (MHRA) Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

New minor risk - Profitability

Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director

Acticor Biotech SAS Provides an Update on the Progress of Its Clinical Programs with Glenzocimab

Acticor Biotech SAS Provides an Update on the US Regulatory Discussion with the FDA

Acticor Biotech Receives European Medicines Agency Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Acticor Biotech SAS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

Acticor Biotech SAS Receives Priority Medicines Status from the European Medicines Agency for Its Drug Candidate, Glenzocimab

Acticor Biotech SAS Announces Issuance of Patent in Europe for Glenzocimab, Its Innovative Product for the Treatment of Cardiovascular Emergencies

No longer forecast to breakeven

Less than half of directors are independent

Forecast to breakeven in 2023

Acticor Biotech Announces Positive Results from Its ACTIMIS PHASE 1b/2a Study in Patients With Acute Ischemic Stroke (AIS)

Acticor Biotech Announces Results of the Phase 2 Garden Study in Covid-19-Related Acute Respiratory Distress Syndrome

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age